Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 325 versus CONRAY 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 325 versus CONRAY 400.
CONRAY 325 vs CONRAY 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays by blocking photons, allowing visualization of blood vessels and tissues.
Iodinated radiocontrast agent that attenuates X-rays by blocking their passage, thereby enhancing radiographic contrast in imaging procedures.
Intravenous: 1.0-2.0 mL/kg (325 mg I/mL) for contrast imaging; maximum total dose 250 mL.
0.5-1.0 mL/kg (up to 150 mL total) intravenously, maximum 150 mL per procedure.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. May be prolonged in renal impairment.
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged significantly.
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<5%).
Primarily renal: >95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion: negligible (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent